November 30, 2021
A combination therapy pairing Eisai’s multikinase inhibitor Lenvima (lenvatinib) and US Merck’s PD-1 inhibitor Keytruda (pembrolizumab) was approved in Europe for two indications related to renal cell carcinoma (RCC) and endometrial carcinoma. More specifically, the European Commission approved the combo...read more